A detailed history of Koss Olinger Consulting, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Koss Olinger Consulting, LLC holds 896 shares of VRTX stock, worth $404,069. This represents 0.04% of its overall portfolio holdings.

Number of Shares
896
Previous 861 4.07%
Holding current value
$404,069
Previous $403,000 3.23%
% of portfolio
0.04%
Previous 0.04%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

BUY
$460.0 - $505.78 $16,100 - $17,702
35 Added 4.07%
896 $416,000
Q2 2024

Aug 06, 2024

BUY
$392.81 - $485.53 $338,209 - $418,041
861 New
861 $403,000
Q4 2023

Feb 13, 2024

SELL
$343.0 - $410.68 $134,799 - $161,397
-393 Reduced 10.06%
3,512 $1.43 Million
Q3 2023

Oct 10, 2023

SELL
$338.18 - $362.46 $22,996 - $24,647
-68 Reduced 1.71%
3,905 $1.36 Million
Q1 2023

May 12, 2023

BUY
$283.23 - $323.1 $14,444 - $16,478
51 Added 1.3%
3,973 $1.25 Million
Q4 2022

Feb 13, 2023

SELL
$285.76 - $321.48 $837,562 - $942,257
-2,931 Reduced 42.77%
3,922 $1.13 Million
Q3 2022

Nov 14, 2022

SELL
$273.83 - $305.53 $40,800 - $45,523
-149 Reduced 2.13%
6,853 $1.98 Million
Q2 2022

Jul 08, 2022

SELL
$234.96 - $292.55 $316,256 - $393,772
-1,346 Reduced 16.12%
7,002 $1.97 Million
Q1 2022

May 06, 2022

BUY
$221.42 - $260.97 $50,483 - $59,501
228 Added 2.81%
8,348 $2.18 Million
Q4 2021

Feb 07, 2022

BUY
$177.01 - $223.45 $770,878 - $973,124
4,355 Added 115.67%
8,120 $1.78 Million
Q3 2021

Nov 09, 2021

BUY
$181.39 - $202.99 $682,933 - $764,257
3,765 New
3,765 $683,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Koss Olinger Consulting, LLC Portfolio

Follow Koss Olinger Consulting, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Koss Olinger Consulting, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Koss Olinger Consulting, LLC with notifications on news.